Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis

Dry eye disease (DED) is a multifactorial disease that causes ocular discomfort and visual impairment on a damaged ocular surface. Lifitegrast, a novel T-cell integrin antagonist, was approved in the United States in July 2016 as a 5% (50 mg/mL) ophthalmic solution for DED management. Currently, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing-Xing, Tsai, Yi-Yu, Lai, Chun-Ting, Li, You-Ling, Wu, Ying-Hsuen, Chiang, Chun-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456613/
https://www.ncbi.nlm.nih.gov/pubmed/36078948
http://dx.doi.org/10.3390/jcm11175014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456613/
https://www.ncbi.nlm.nih.gov/pubmed/36078948
http://dx.doi.org/10.3390/jcm11175014

Ejemplares similares